Nexavar Tablet, Film Coated
NDC Package 50419-488-58
Package Information
Nexavar (sorafenib) tablets is sorafenib is used to treat kidney, liver, and thyroid cancer. This formulation utilizes a tablet, film coated delivery system. Marketed by Bayer Healthcare Pharmaceuticals Inc., this product is identified by NDC 50419-488 and is authorized under FDA application NDA021923.
Identification & Billing
- RxCUI: 597747 - SORAfenib 200 MG Oral Tablet
- RxCUI: 597747 - sorafenib 200 MG Oral Tablet
- RxCUI: 597747 - sorafenib (as sorafenib tosylate) 200 MG Oral Tablet
- RxCUI: 615979 - NexAVAR 200 MG Oral Tablet
- RxCUI: 615979 - sorafenib 200 MG Oral Tablet [Nexavar]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50419 - Bayer Healthcare Pharmaceuticals Inc.
- 50419-488 - Nexavar
- 50419-488-58 - 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 50419-488 - Nexavar
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50419-488-58 identifies a specific commercial package of 120 tablet, film coated in 1 bottle, plastic of Nexavar, a human prescription drug labeled by Bayer Healthcare Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 120 billable units per package. This tablet, film coated is formulated for oral use and contains sorafenib as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Pharmaceuticals Inc. on December 20, 2005. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Sorafenib is used to treat kidney, liver, and thyroid cancer. It works by slowing or stopping the growth of cancer cells.
How is this Bayer Healthcare Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50419048858. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.